GV20 Therapeutics
Clinical Trials
2
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Study of GV20-0251 in Participants With Solid Tumor Malignancies
- Conditions
- Solid Tumor CancerAdult Refractory CancerEndometrial Carcinoma (EC)Squamous Head and Neck CarcinomapMMR/MSS Adenocarcinoma of the Colon or RectumNon-Small Cell Lung CancerMelanomaHCC - Hepatocellular CarcinomaSmall Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-07-17
- Last Posted Date
- 2025-08-20
- Lead Sponsor
- GV20 Therapeutics
- Target Recruit Count
- 350
- Registration Number
- NCT07070518
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Conditions
- Solid Tumor, AdultRefractory CancerEndometrial Carcinoma (EC)Squamous Head and Neck CarcinomapMMR/MSS Adenocarcinoma of the Colon or RectumCutaneous MelanomaNon-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-12-30
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- GV20 Therapeutics
- Target Recruit Count
- 268
- Registration Number
- NCT05669430
- Locations
- 🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸HealthONE Clinic Services Oncology - Hematology, LLC d/b/a Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸Yale University, New Haven, Connecticut, United States
News
GV20 Therapeutics to Present AI-Designed Immune Checkpoint Inhibitor Data for Advanced Melanoma at ASCO 2025
GV20 Therapeutics will present updated Phase 1 data on GV20-0251, the first AI-designed antibody targeting the novel immune checkpoint IGSF8, at ASCO 2025.
GV20 Therapeutics Partners with Mitsubishi Tanabe to Develop Novel AI-Discovered Antibody-Drug Conjugates
GV20 Therapeutics has formed a strategic research collaboration with Mitsubishi Tanabe Pharma Corporation to develop first-in-class antibody-drug conjugates targeting novel tumor antigens.
GV20 Therapeutics Reports First Clinical Data for AI-Designed Checkpoint Inhibitor GV20-0251 in Advanced Solid Tumors
GV20 Therapeutics presented Phase 1 data for GV20-0251, marking the first clinical results for an AI-designed antibody targeting an AI-predicted immune checkpoint IGSF8.